Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10201/20628

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorPrendergast, G.C.es
dc.date.accessioned2011-05-11T10:55:26Z-
dc.date.available2011-05-11T10:55:26Z-
dc.date.issued2001-
dc.identifier.issn0213-3911es
dc.identifier.urihttp://hdl.handle.net/10201/20628-
dc.description.abstractA long-standing goal in cancer research is to identify cellular functions that have selective roles in regulating neoplastic pathophysiology. Farnesyltransferase inhibitors (FTIs) are a novel class of cancer chemotherapeutics which have little effect on normal cell physiology but which inhibit or reverse malignant cell phenotypes. FTIs were originally developed as a strategy to inhibit oncogenic Ras, the activity of which depends upon posttranslational farnesylation. However, recent work indicates the antineoplastic effects of FTIs are not linked to Ras inhibition but instead to alteration of RhoB, a small GTPase of the Rho family of cytoskeletal regulators that controls trafficking of cell surface receptors. Rho proteins integrate signals from integrins and cytokine receptors with cell shape via the actin cytoskeleton. A connection between FTIs and Rho alteration is interesting given that histological differences have long been used to define clinical cancer. RhoB is dispensable for normal cell growth and differentiation in mice. Thus, research into the antineoplastic effects of FTIs has led to the identification of a function(s) that is unnecessary for normal cell physiology but crucial for controlling malignant phenotypes.es
dc.formatapplication/pdfes
dc.format.extent7es
dc.languageenges
dc.publisherMurcia : F. Hernándezes
dc.relation.ispartofHistology and histopathologyes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectCanceres
dc.subjectExperimental therapeuticses
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes
dc.titleFarnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiologyes
dc.typeinfo:eu-repo/semantics/articlees
Aparece en las colecciones:Vol.16, nº 1 (2001)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.pdf4,84 MBAdobe PDFVista previa
Visualizar/Abrir


Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.